Stevanato S.p.a (STVN) Stock
Global primary packaging supplier for pharmaceutical companies. Here's the price, business snapshot, and what's worth knowing about Stevanato S.p.a in September 2026.
Stevanato Group S.p.A. (STVN) is an Italian-based supplier of primary packaging and drug containment solutions for the pharmaceutical and biotechnology industries. The company produces glass vials, syringes, cartridges and other sterile containment systems, and offers assembly and inspection services to customers developing vaccines, biologics and injectable medicines. With a market capitalisation of about $7.19 billion, Stevanato’s performance is linked to global pharmaceutical demand, adoption of advanced delivery formats and regulatory standards for sterile packaging. The business is capital-intensive and benefits from long-term customer contracts, but faces risks such as raw material costs, currency fluctuations and customer concentration. Investors should weigh growth prospects from biologics and onshoring trends against cyclical healthcare spending and execution risks. This content is educational only and not personal advice; values can fall as well as rise, and past performance is not a reliable indicator of future returns.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Stevanato Group's stock, expecting it to rise to $26.20.
Financial Health
Stevanato Group is producing solid revenue and cash flow, indicating strong overall financial performance.
Dividend
Stevanato Group's low dividend yield of 0.3% may not provide much income for investors. If you invested $1000 you would be paid $3 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Strong demand drivers
Rising biologics and injectable therapies support long-term demand, though growth depends on customer contracts and industry cycles.
Global manufacturing reach
A footprint across regions helps serve multinational pharma firms, but also exposes the company to currency and supply-chain risks.
Innovation and risks
Investments in advanced containment and inspection can create competitive edge; however, the business is capital-intensive and execution matters.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
